Fighting the heart failure Pandemic
Welcome to CardiNor
New publication – secretoneurin provide prognostic information in patients with chronic, stable HF
Secretoneurin (SN) data from the multicenter study GISSI Heart Failure Trial was published in Clinical Biochemistry, volume 118, August 2023.
The study was performed using the CE-marked CardiNor Secretoneurin ELISA Assay.
Individual patients with chronic heart failure (HF) have very different prognosis, also within subgroups classified according to etiology and left ventricular ejection fraction (LVEF). Circulating protein biomarkers have the potential to identify vulnerable patients that could benefit from special follow-up and uptitration of guideline-directed medical therapy. As B-type natriuretic peptide (BNP)-guided therapy has not demonstrated clear benefit over symptom-based management in major randomized-controlled trial, there is a need to identify additional prognostic biomarkers. Hence, biomarkers that provide incremental prognostic information to BNP, and preferably across the spectrum of LVEF, may prove important for future personalized management strategies in HF patients.
Circulating SN concentrations have been found to provide prognostic information in patients with acute heart failure. In this study plasma SN concentrations were measured at randomisation (n = 1224) and after 3 months (n = 1103) in patients with chronic, stable heart failure from the GISSI-HF study, and the aim was to assess whether SN would improve prognostication also in patients with chronic heart failure.
The authors H. Røsjø, J. Meessen, A. H. Ottesen, R. Latini and T. Omland, on behalf of the GISSI-HF Investigators highlighted that
- SN concentrations separate stable heart failure patients with a poor and favorable prognosis
- SN concentrations were not different between patients with Left Ventricle Ejection Fraction (LVEF) <50% and LVEF ≥50%
- SN concentrations provided additional prognostic information to established risk indices and biomarkers in patients with stable heart failure.
The article is free, very useful and can be downloaded here:
Featured in CLI 31.10.2022:
Secretoneurin: a potential complementary cardiovascular biomarker
Secretoneurin is a novel prognostic biomarker that may predict mortality in heart failure and the occurrence of ventricular arrhythmias. Clinical Laboratory International (CLI) caught up with Professor Torbjørn Omland (University of Oslo, Oslo, Norway) to find out more about it.
Secretoneurin: the next biomarker for cardiovascular disease.
Secretoneurin is a small neuropeptide detectable in the blood and is strong predictor for mortality in several patient cohorts with underlying cardiovascular disease. Here CardiNor introduce themselves and their work to develop a secretoneurin test to use as part of a biomarker panel for cardiovascular disease.
CardiNor Contact Information
0349 Oslo, Norway